113 related articles for article (PubMed ID: 25420854)
21. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tolerance and safety of conversion from mycophenolate mofetil to enteric-coated mycophenolic acid in renal transplant recipients.
Qiao LW; Qu QS; Jiang X
J Biol Regul Homeost Agents; 2017; 31(1):141-146. PubMed ID: 28337883
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of a Quadruple Regimen Compared with Triple Regimens in Patients with Mycophenolic Acid-Related Gastrointestinal Complications After Renal Transplantation: A Short-Term Single-Center Study.
Peng Z; Xian W; Sun H; Li E; Geng L; Tian J
Ann Transplant; 2020 Feb; 25():e919875. PubMed ID: 32107364
[TBL] [Abstract][Full Text] [Related]
24. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
25. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
26. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
Barrera-Pulido L; Alamo-Martínez JM; Marín-Gómez LM; Suárez-Artacho G; Bernal-Bellido C; Domínguez-Usero D; Tallón-Aguilar L; Pareja-Ciuró F; Sousa-Martín JM; García-González I; Gómez-Bravo MA
Transplant Proc; 2009; 41(6):2192-4. PubMed ID: 19715870
[TBL] [Abstract][Full Text] [Related]
27. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
28. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
29. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
[TBL] [Abstract][Full Text] [Related]
31. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients.
Toledo AH; Hendrix L; Buchholz V; Fisher E; Newton K; Smith C; Gerber DA
Clin Transplant; 2012; 26(1):156-63. PubMed ID: 21470310
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
[TBL] [Abstract][Full Text] [Related]
34. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
36. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
37. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus.
Mohsin N; Al-Raisi F; Militsala E; Kamble P; Abdel Razek E; Baddruddin M
Transplant Proc; 2015 May; 47(4):1122-4. PubMed ID: 26036534
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
